Risk of multiple drug interactions potentially linked to safety in patients receiving pangenotypic direct-acting antivirals for the treatment of Hepatitis C

Risk of multiple drug interactions potentially linked to safety in patients receiving pangenotypic direct-acting antivirals for the treatment of Hepatitis C

Introduction and Objectives: Previous studies have evaluated the risk of drug-drug interactions (DDI) in HCV patients receiving pangenotypic direct-acting antivirals (pDAA), but all are based on pairwise interaction. The aim of the study was to describe the prevalence of the risk of potential multip...

Full description

Bibliographic Details
Main Authors:	J Mendez-Navarro, J Turnes, A García-Herola, R Morillo, M Méndez, M Rueda, C Hernández, A Sicras-Mainar
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268122001661

Similar Items

P- 24 RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C
by: Juan Turnes, et al.
Published: (2023-03-01)

Pangenotypic Direct Acting Antivirals Treatment for Chronic Hepatitis C Infection
by: Juferdy Kurniawan
Published: (2020-07-01)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
by: Dorota Zarębska-Michaluk, et al.
Published: (2022-01-01)

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
by: Fagiuoli S, et al.
Published: (2023-01-01)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
by: Dorota Zarębska-Michaluk, et al.
Published: (2021-07-01)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
by: Bin Niu, et al.
Published: (2023-04-01)

Recombinant Full-Length Hepatitis C Virus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies
by: Tianli Lin, et al.
Published: (2022-06-01)

Alcohol Use and Long‐Term Outcomes Among U.S. Veterans Who Received Direct‐Acting Antivirals for Hepatitis C Treatment
by: Nicole J. Kim, et al.
Published: (2020-02-01)

Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact
by: Antoni Sicras-Mainar, et al.
Published: (2014-12-01)

Characterisation of Hepatitis C Virus antiviral resistance in the era of direct acting antivirals
by: Smith, D
Published: (2019)

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
by: Yen-Chun Chen, et al.
Published: (2022-02-01)

Reversibility of some oxidative stress markers in chronic hepatitis C patients after receiving direct-acting antiviral agents
by: Pin-Nan Cheng, et al.
Published: (2023-03-01)

Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
by: Yu Fang, et al.
Published: (2023-07-01)

The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia
by: Sumaiah J. Alarfaj, et al.
Published: (2022-10-01)

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
by: Foster, G, et al.
Published: (2016)

Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine
by: Verma, Malvika, et al.
Published: (2020)

Effect of gender difference on psychiatric outcomes for hepatitis C virus patients receiving direct-acting antivirals in Egyptian population: a cohort study
by: Zainab Gaber Mahran, et al.
Published: (2022-12-01)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
by: Hang Zhang, et al.
Published: (2023-11-01)

Safety and Efficacy of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C in Population Aged 60 Years and Older in Upper Egypt
by: Ali A. Ghweil, et al.
Published: (2023-01-01)

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
by: Camila C. Simoes, et al.
Published: (2019-08-01)

Long-term durability of sustained virologic response for hepatitis C virus infection in solid organ transplant recipients receiving direct-acting antivirals
by: Chen-Hua Liu, et al.
Published: (2023-08-01)

Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
by: Jesús Molina, et al.
Published: (2023-04-01)

Liver cT1 decreases following direct acting antiviral therapy in patients with chronic hepatitis C virus
by: Jayaswal, A, et al.
Published: (2020)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
by: Toshifumi Tada, et al.
Published: (2022-01-01)

Treatment of hepatitis C using direct-acting antiviral (DAA) agents in patients undergoing liver transplantation
by: V. E. Syutkin, et al.
Published: (2016-02-01)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
by: Christiana Graf, et al.
Published: (2020-08-01)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
by: Erica Nicola Lynch, et al.
Published: (2023-03-01)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
by: Mohammad Said Ramadan, et al.
Published: (2022-09-01)

Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals
by: Bader Faiyaz Zuberi
Published: (2017-08-01)

Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals
by: Bader Faiyaz Zuberi
Published: (2017-08-01)

Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism
by: Jucéli Márcia Hendges Sparvoli, et al.
Published: (2023-01-01)

Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
by: Mary-Anne Doyle, et al.
Published: (2019-03-01)

Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
by: Elisabetta Loggi, et al.
Published: (2017-01-01)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
by: Daniel Millian, et al.
Published: (2023-04-01)

Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan
by: M. N. Raza, et al.
Published: (2021-12-01)

Treatment of the chronic hepatitis C complicated by mixed cryoglobulinemia with direct-acting antiviral agents
by: N. V. Dunaeva, et al.
Published: (2018-12-01)

Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection
by: El-Araby Mohamed Ibrahim Shalaby, et al.
Published: (2023-06-01)

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
by: Cheung, M, et al.
Published: (2016)

Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
by: Ghaydaa A. Shehata, et al.
Published: (2022-12-01)

Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C
by: A. I. Gubenko, et al.
Published: (2023-12-01)